Table 3 PSM between LD- and LD+ Patients Resulting in 74 Pairs of Matched Patients

Age, median (range)

54 (27–87)

56 (36–77)

0.694

53 (31–73)

56 (36–77)

0.192

Gender (male), n (%)

121 (62.4)

48 (64.0)

0.804

47 (63.5)

48 (64.9)

0.864

HBsAg positive, n (%)

107 (55.2)

41 (54.7)

0.942

44 (59.5)

40 (54.1)

0.507

Child-Pugh Class (B), n (%)

10 (5.2)

5 (6.7)

0.851

5 (6.8)

5 (6.8)

> 0.99

AST, IU/L, median (range)

31 (10–701)

31 (10–451)

0464

30 (14–701)

31 (10–451)

0.681

CA-199 (U/mL), median (range)

35.4 (0–1000)

43.8 (0–5533)

0.102

33.4 (0–1000)

48.1 (0–5533)

0.064

Tumor diameter (cm), median (range)

6 (0.5–18.4)

6.7 (2–17)

0.034

6 (0.5–15)

6.7 (2–17)

0.687

Unifocal lesions, n (%)

121 (62.4)

40 (53.3)

0.175

45 (60.8)

40 (54.1)

0.406

Major hepatectomy, n (%)

116 (59.8)

55 (73.3)

0.039

50 (67.6)

54 (73.0)

0.472

Negative surgical margin, n (%)

182 (93.8)

70 (93.3)

> 0.99

69 (93.2)

69 (93.2)

> 0.99

Blood loss (mL), median (range)

300 (50–4000)

300 (20–1500)

0.064

300 (100–4000)

300 (20–1500)

> 0.99

Transfusion, n (%)

28 (14.4)

20 (26.7)

0.019

16 (21.6)

20 (27.0)

> 0.99

Major complications, n (%)

14 (7.2)

4 (5.3)

0.579

7 (9.5)

4 (5.4)

0.347

Tumor differentiation, poor, n (%)

59 (30.4)

24 (32.0)

0.800

18 (24.3)

23 (31.1)

0.358

Macrovascular invasion, n (%)

21 (10.8)

13 (17.3)

0.150

11 (14.9)

12 (16.2)

0.821

Microvascular invasion, n (%)

34 (17.5)

15 (20.0)

0.637

13 (17.6)

15 (20.3)

0.675

Perineural invasion, n (%)

16 (8.2)

5 (6.7)

0.665

2 (2.7)

5 (6.8)

0.442

Periductal invasion, n (%)

12 (6.2)

4 (5.3)

> 0.99

2 (2.7)

4 (5.4)

0.681

Cirrhosis, n (%)

110 (56.7)

36 (48.0)

0.199

45 (60.8)

36 (48.6)

0.137

Antiviral therapy, n (%)

53 (27.3)

17 (22.7)

0.435

14 (18.9)

17 (23)

0.545

Adjuvant therapy, n (%)

67 (34.5)

30 (40.0)

0.403

35 (47.3)

29 (39.92)

0.319